REMS That Block Generics Are ‘Major’ Problem For FDA, Jenkins Says
This article was originally published in Pharmaceutical Approvals Monthly
Chief of new drugs office notes unintended consequence of safety legislation is thwarting development of ANDAs and biosimilars.
You may also be interested in...
GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
The pending Supreme Court decision on the Affordable Care Act may have forced negotiators to finish quicker than they would have liked as legislators indicate some more time may have produced an agreement on track-and-trace standards; stakeholders may question whether the bill could have been improved had the deadline not been looming.